Cargando…
Indirect Regulation and Equilibrium of p35 and p40 Subunits of Interleukin (IL)-12/23 by Ustekinumab in Psoriasis Treatment
BACKGROUND: Ustekinumab, a human-derived monoclonal antibody that targets the p40 subunit of interleukin (IL)-12 and IL-23, has excellent clinical efficacy and safety in treating psoriasis, with a long half-life. However, no reports have described the use of human skin/serum samples to elucidate its...
Autores principales: | Zhou, Jiong, Shen, Ji-Yang, Liu, Lun-Fei, Chen, Ji-Su, Dou, Ting-Ting, Zheng, Min, Cai, Sui-Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977627/ https://www.ncbi.nlm.nih.gov/pubmed/31910201 http://dx.doi.org/10.12659/MSM.920371 |
Ejemplares similares
-
Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis
por: Koutruba, Nora, et al.
Publicado: (2010) -
Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris
por: Lee, Edmund, et al.
Publicado: (2004) -
Erythema multiforme after initiation of anti interleukin-12/23 (ustekinumab) treatment for plaque psoriasis
por: Burlando, Martina, et al.
Publicado: (2020) -
The p40 Subunit of Interleukin (IL)-12 Promotes Stabilization and Export of the p35 Subunit: IMPLICATIONS FOR IMPROVED IL-12 CYTOKINE PRODUCTION
por: Jalah, Rashmi, et al.
Publicado: (2013) -
Ustekinumab: differential use in psoriasis
por: Uhlenhake, Elizabeth E, et al.
Publicado: (2011)